Skip to search formSkip to main contentSkip to account menu

volitinib

Known as: SAVOLITINIB 
An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Volitinib selectively binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

AZD6094HMPL-504
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Overall survival results for durvalumab and savolitinib in metastatic papillary renal cancer.
619Background: There is a strong rationale for investigating MET and PD-L1 inhibition in metastatic papillary renal cancer (PRC… 
2020
2020
SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).
5002Background: PRCC is the most common type of non-clear cell RCC, accounting for 10–15% of renal malignancies. As a subset of… 
2020
2020
非小细胞肺癌MET基因突变的机制及靶向药物研究进展
  • Sen HanXu MaJ. Fang
  • Zhongguo fei ai za zhi = Chinese journal of lung…
  • 2020
  • Corpus ID: 220730604
间质-上皮细胞转化因子（mesenchymal-epithelial transition factor, MET）基因是非小细胞肺癌（non-small cell lung cancer, NSCLC）的一种重要肿瘤驱动基因，针对MET 14… 
2019
2019
Combo Therapy Beats Back Relapsed NSCLC.
Patients with EGFR-mutant non-small cell lung cancer who develop MET-driven resistance to an EGFR inhibitor-be it a first… 
2017
2017
Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.
A rapid, simple, and accurate procedure was developed and validated for the simultaneous quantification of two anticancer agents… 
2017
2017
VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met…
4024Background: The VIKTORY trial is a biomarker-based umbrella trial in GC. Methods: See table below. Results: From June 2014 to… 
2017
2017
Savolitinib for MET-driven papillary renal cell carcinoma.
2017
2017
A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).
436Background: Savolitinib (HMPL504/Volitinib, AZD6094) is a potent, selective MET inhibitor (IC50 of 4nM). MET and its ligand… 
2013
2013
Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor .
Volitinib is a novel selective cMet inhibitor. This study is to evaluate its preclinical ADME/PK profile. Volitinib has high… 
2013
2013
Abstract 971: Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquiredMetgene amplification.
It is well recognized that non-small cell lung carcinoma (NSCLC) patients with activating EGFR mutations will develop drug… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)